Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.
News|Articles|April 21, 2026
When First-Line Fails: The Rising Threat of Treatment-Resistant Dermatoses
Author(s)Tim Smith
Fact checked by: Victoria Johnson
There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.
Advertisement
Advertisement
The emergence of Trichophyton indotineae is not just a story about a single
Related to this article
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
Oral bitopertin met all primary and secondary endpoints in the phase 3 APOLLO trial in EPP, cutting PPIX and increasing pain-free time in light.
Yoseph Dalia, MD, discusses diagnosing and treating pseudofolliculitis barbae, its occupational impact, and barriers to care in skin of color.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
Advertisement
Advertisement